High Dose Chemotherapy and Autologous Transplant for Breast Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2007 by Stanford University.
Recruitment status was  Active, not recruiting
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
First received: September 14, 2005
Last updated: July 10, 2007
Last verified: July 2007
To determine survival outcomes for patients with chemosensitive brest cancer after treatment with high dose chemotherapy

Condition Intervention Phase
Graft vs Host Disease
Procedure: high dose chemo and auto hematopoietic cell transplant
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: High Dose Chemotherapy and Peripheral Blood Progenitor Cell Rescue for Patients With Breast Cancer

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Survival

Estimated Study Completion Date: March 2005

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Stage II, III or IV breast cancer
  • chemosensitive
  • adequate organ function

Exclusion Criteria:

  • prior transplant,
  • life threatening disease
  • brain metastases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00186641

United States, California
Stanford University Cancer Center
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Principal Investigator: Ginna Laport, MD Stanford University
  More Information

ClinicalTrials.gov Identifier: NCT00186641     History of Changes
Other Study ID Numbers: BMT42 
Study First Received: September 14, 2005
Last Updated: July 10, 2007
Health Authority: United States: Food and Drug Administration

Keywords provided by Stanford University:
chronic Graft vs Host Disease

Additional relevant MeSH terms:
Graft vs Host Disease
Immune System Diseases

ClinicalTrials.gov processed this record on April 27, 2016